MyRealWorld™ MG (MRW MG) is an international study assessing the impact of Myasthenia Gravis on patients’ lives.

Working with patient organizations from ten countries (US, Japan, Germany, UK, France, Italy, Spain, Canada, Belgium, Denmark), biotechnology company argenx sponsors this innovative study. To be part of this meaningful research to better understand the lives of people living with Myasthenia Gravis, visit https://myrealworld.com/
 

If you have any questions, please email us at mg@vitaccess.com.